Evidence map›Paper›PMID 35799670›Full record

ArticleComputational and mathematical methods in medicine2022

Effects of Afatinib on Development of Non-Small-Cell Lung Cancer by Regulating Activity of Wnt/

Yue Wu, Jiajing Zhang, Changping Yun, Chenchen Dong, Ye Tian

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Computational and mathematical methods in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yue WuSecond Department of Respiratory Medicine, The Second Affiliated Hospital of Qiqihar Medical College, Qiqihar, 161001 Heilongjiang, China.
Jiajing ZhangSecond Department of Respiratory Medicine, The Second Affiliated Hospital of Qiqihar Medical College, Qiqihar, 161001 Heilongjiang, China.
Changping YunSecond Department of Respiratory Medicine, The Second Affiliated Hospital of Qiqihar Medical College, Qiqihar, 161001 Heilongjiang, China.
Chenchen DongSecond Department of Respiratory Medicine, The Second Affiliated Hospital of Qiqihar Medical College, Qiqihar, 161001 Heilongjiang, China.
Ye TianSecond Department of Respiratory Medicine, The Second Affiliated Hospital of Qiqihar Medical College, Qiqihar, 161001 Heilongjiang, China.ORCID https://orcid.org/0000-0001-5515-171X
Qiqihar Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer has been one of the deadliest cancers in the world. Afatinib is an ErbB family irreversible blocker that was authorized by the FDA and EMA in 2013 for the treatment of advanced EGFR mutation-positive NSCLC. Therefore, we aim to discover the impact of Afatinib on the development of non-small-cell lung cancer (NSCLC) via modulating the Wnt/

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAfatinibBiomarkers, TumorHumansMutationProtein Kinase InhibitorsWnt Signaling PathwayAfatinibBiomarkers, TumorProtein Kinase Inhibitors

Identifiers

PMID35799670
PMCPMC9256313
OpenAlexW4283687852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.